High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 2, 2001, Pages 138-142

  Milla Santos, A ^a   Milla, L ^a   Rallo, L ^a   Solano, V ^a  

^a Medical Oncology Department   (Spain)

Author keywords

Advanced breast cancer; Docetaxel; High dose epirubicin; Lenograstim support

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREMEDICATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0035049928     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200104000-00008     Document Type: Article

References (24)

1. New directions for breast cancer therapeutic research
2. Critical evaluation of prognostic factors
3. The anthracyclines: Will we ever find a better doxorubicin?
4. New treatments for breast cancer
5. The importance of dose intensity in chemotherapy of metastatic breast cancer
6. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
7. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v. fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
8. Preliminary phase I study of 4′-epiadriamycin
9. 2 epirubicin
10. Prospects with docetaxel in the treatment of patients with breast cancer
11. Docetaxel in combination: A step forward
12. New approaches to the treatment of advanced breast cancer
13. Non-parametric estimation from incomplete observations
14. Phase I-II study of Taxotere (TXTR) in combination with Adryamicin (AD) as first-line chemotherapy in patients with metastatic breast cancer (MBC)
15. Clinical applications of colony stimulating factors
16. Effect of filgrastim (r-metHUG-CSF) on oral mucositis in patients with small cell lung cancer receiving chemotherapy cyclophosphamide, doxorubicin and etoposide
17. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation
18. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer
19. A phase I/II study of docetaxel and epirubicin in advanced breast cancer
20. Phase II trial evaluating Adriamycin and Taxotere (A/T) with GM-CSF support as first-line therapy for women with metastatic breast cancer (MBC)
21. Phase II study of sequential docetaxel (Taxotere, TXT) and doxorubicin (DOX) as primary chemotherapy (CT) for large operable breast cancer (BC)
22. The safety of doxorubicin and docetaxel in a phase II trial of neoadjuvant treatment of locally advanced breast cancer
23. Neoadjuvant chemotherapy with sequential doxorubicin (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC): A pilot study